Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Roche Holding AG’s RHHBY subsidiary, Genentech announced that the FDA has approved a label expansion for its arthritis drug, Actemra. The FDA approved a subcutaneous (SC) formulation — a prefilled syringe that can be injected at home —of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older.